FDA pilot lets AI medical devices reach market pre-authorization — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA launched the TEMPO pilot program, which provisionally allows generative AI medical device developers to release products on the market without prior marketing authorization.
- Cadence and Limbic are among four devices recently accepted into TEMPO, joining other digital health companies in the cohort.
- The pilot is designed to expand the pool of technologies available for the Medicare ACCESS model, an existing experiment in paying for chronic-condition management tools for beneficiaries.
- The program also gives the FDA and participating companies a chance to test AI regulation in real-world settings rather than purely in pre-market review.
- Generative AI medical devices — products whose care decisions rely on AI — face an unsettled regulatory framework, and TEMPO represents a provisional workaround while the FDA works out its approach.
Why it matters: Four generative AI device makers — including Cadence and Limbic — can now reach Medicare chronic-care patients under ACCESS without the usual pre-market authorization, meaning the FDA is using real-world deployment as its de facto regulatory laboratory while it builds permanent rules for generative AI in medicine.
Ask SkimNews
